Camel Intestinal Mucosa Extraction for Stable Unfractionated Heparin Supply

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The reliance on porcine intestine mucosa for unfractionated heparin production is insufficient to meet global demand and susceptible to shortages due to epidemics, necessitating the exploration of alternative sources.

Innovation Solution

A method for extracting unfractionated heparin from camel intestinal mucosa involves a series of steps including washing, pressing, calcification, and purification processes to obtain high-quality heparin, utilizing calcium chloride, sodium carbonate, hydrogen peroxide, and protease to achieve a pure mucosa extraction and subsequent purification.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If porcine intestine mucosa is used as the source for unfractionated heparin production, then current production can be maintained, but global demand cannot be met and shortages occur due to epidemics

Engineering Contradiction:
Improveunfractionated heparin production volumeVSAvoidsupply stability
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The patent changes the source parameter from porcine intestine to camel intestine mucosa, exploring a new animal source to diversify supply and reduce dependence on a single source, thereby improving supply stability while maintaining production volume

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs a multi-step extraction process combining multiple chemicals (calcium chloride, sodium carbonate, hydrogen peroxide, protease, ethanol) to systematically extract and purify heparin from camel intestine, creating a reliable production method from an alternative source

Inventive Principle:
Principle #40Composite materials

2Ease of manufacture

If traditional extraction methods are used, then extraction process is simpler, but mucosa extraction efficiency is low and quality is poor

Engineering Contradiction:
Improveextraction process simplicityVSAvoidmucosa extraction efficiency
Core Design Contradiction:
Ease of manufactureVSProductivity

Solution Approach 1:

The patent applies preliminary actions including washing the intestine with water, massaging to loosen mucosa, soaking in water bath, and pressing to release mucosa before chemical extraction. These preliminary mechanical and physical treatments prepare the material for more efficient chemical extraction, improving both yield and quality

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent uses multiple intermediary substances in sequence: calcium chloride for calcification, sodium carbonate for removing excess calcium, hydrogen peroxide for oxidation and purification, protease for protein degradation, and ethanol for precipitation. Each intermediary facilitates the next step, systematically improving extraction efficiency and mucosa quality

Inventive Principle:
Principle #24Intermediary (Mediator)

3Manufacturing precision

If multiple chemical treatment steps are applied, then mucosa purity and heparin quality improve, but process complexity increases

Engineering Contradiction:
Improveheparin purityVSAvoidextraction process complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent segments the extraction process into distinct sequential steps: washing and mechanical separation, calcification with calcium chloride, removal of excess calcium with sodium carbonate, oxidation with hydrogen peroxide, proteolytic digestion with protease, and precipitation with ethanol. Each segment performs a specific function, making the complex process manageable and controllable while achieving high purity

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent systematically changes chemical parameters at each step: pH adjustment through calcium chloride and sodium carbonate addition, oxidation state changes with hydrogen peroxide, protein breakdown through protease treatment, and solubility changes with ethanol precipitation. These parameter changes drive the purification process forward, achieving high heparin purity despite process complexity

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method yields pure unfractionated heparin with a molecular weight of 23,567 Daltons, lower activated partial thromboplastin time activity, and improved anticoagulant potency, reducing the risk of bleeding and providing a stable source for pharmaceutical use.

Implementation Method 1

adding calcium chloride to the mucosa to obtain a first mixture, wherein the calcium chloride calcifies the mucosa

Methodology Applied
Scientific EffectCalcification:

Implementation Method 2

adding hydrogen peroxide to the second mixture to obtain pure mucosa

Methodology Applied
Scientific EffectOxidation: Oxidation

Implementation Method 3

adding protease to the pure mucosa to obtain a fourth mixture, and leaving the fourth mixture to react for at least about 2 hours to at least about 5 hours

Methodology Applied
Scientific EffectEnzymatic degradation: Enzyme

Implementation Method 4

removing excessive calcium chloride from the mixture by adding sodium carbonate to create a second mixture

Methodology Applied
Scientific EffectNeutralization:

Implementation Method 5

centrifuging the cooled solution and collecting a first clear solution

Methodology Applied
Scientific EffectCentrifugal separation: Centrifugal Force

Implementation Method 6

adding 0.5 volume of pure ethanol into the seventh mixture; keeping the seventh mixture overnight; and collecting and drying a pure precipitate to obtain a pure unfractionated heparin

Methodology Applied
Scientific EffectPrecipitation: Precipitation

Data Source

PatentUS12565541B1Method for extracting unfractionated heparin from camel intestinal mucosa
Publication Date: 2026.03.03 CAMELX BIOMEDICAL & RESEARCH
  • US12565541B1 patent drawing
  • US12565541B1 patent drawing
  • US12565541B1 patent drawing

AI summary

The present subject matter relates to an extraction procedure of unfractionated heparin from camel intestinal mucosa. The method includes a successful pretreatment procedure to obtain a maximum amount and good quality of mucosa from mast cells in camel intestines. The present disclosures addresses the issues with other heparin sources by providing a very potent unfractionated heparin derived from the intestinal mucosa of camels that are well-adapted desert animals with unique body biochemistry and physiology.